Women with a high genetic predisposition for blood clots are six times more likely to develop a blood clot during the first two years of using contraceptive pills according to a new study from Uppsala University.
T-DXd Tied to Encouraging Survival in HER2-Expressing Gyn Cancers
SEOUL, South Korea — Durable responses with trastuzumab deruxtecan (T-DXd; Enhertu) in heavily pretreated HER2-expressing gynecologic cancers appeared to translate into clinically meaningful survival outcomes,
November 8, 2023